Drug intelligence / Profile preview

BCL-INS-001

Development stage: Preclinical
Lead developer: Bioclonal
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

BCL-INS-001 is a monoclonal antibody currently in preclinical development by Bioclonal, a Spanish biotechnology company. The drug is part of the company's 'Insulin Program' and is designed to target insulin-related pathways, likely for the treatment of metabolic disorders such as diabetes mellitus. As a monoclonal antibody, BCL-INS-001 is intended to provide high specificity in modulating insulin signaling, although its precise mechanism of action—whether it acts as an agonist of the insulin receptor or modulates insulin bioavailability—has not been publicly detailed in depth.

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on BCL-INS-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCL-INS-001.

Explore the full profile